Montelukast

Montelukast (Singulair^®, Abb. [1]) wurde als erster und bislang einziger Vertreter der Leukotrienrezeptorantagonisten im Jahr 1998 in Deutschland zugelassen. Mit dieser Substanzklasse steht ein neues Wirkprinzip für die Therapie des Asthma bronchiale zur Verfügung.

Literatur

• 1 O’Byrne P M. Leukotrienes in the pathogenesis of asthma.  Chest. 1997;  111 27S-34S
• 2 Lynch K R. et al . Characterization of the human cysteinyl leukotriene CysLT1 receptor.  Nature. 1999;  399 789-793
• 3 De Lepeleire I. et al . Montelukast causes prolonged, potent leukotriene D4-receptor antagonism in the airways of patients with asthma.  Clin Pharmacol Ther. 1997;  61 83-92
• 4 Bisgaard H. et al . NO in exhaled air of asthmatic children is reduced by the leukotriene receptor antagonist montelukast.  Am J Respir Crit Care Med. 1999;  160 1227-1231
• 5 Malmstrom K. et al . Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma: A randomized, controlled trial.  Ann Intern Med. 1999;  130 487-495
• 6 Pizzichini E. et al . Montelukast reduces airway eosinophilic inflammation in asthma: a randomized, controlled trial.  Eur Respir J. 1999;  14 12-18
• 7 Nakamura H. et al . Eotaxin and impaired lung function in asthma.  Am J Respir Crit Care Med. 1999;  160 1952-1956
• 8 Reiss T F. et al . Effects of montelukast (MK-0476); a potent cysteinyl leukotriene receptor antagonist, on bronchodilation in asthmatic subjects treated with and without inhaled corticosteroids.  Thorax. 1997;  52 45-48
• 9 Diamant Z. et al . The effect of montelukast (MK-0476), a cysteinyl leukotriene receptor antagonist, on allergen-induced airway responses and sputum cell counts in asthma.  Clin Exp Allergy. 1999;  29 42-51
• 10 Keeling S. DRUGDEX® Editorial Staff. Copyright © MICROMEDEX Inc. 1974 - 2002. DRUGDEX DRUG EVALUATIONS: MONTELUKAST. Medizinisches Informationssystem 2002) 111
• 11 Chiba M. et al . Hepatic microsomal metabolism of montelukast, a potent leukotriene D4 receptor antagonist, in humans.  Drug Metab Dispos. 1997;  25 1022-1031
• 12 Fachinformation Singulair®. Dieckmann Arzneimittel GmbH 2002
• 13 Drazen J M. et al . Treatment of asthma with drugs modifying the leukotriene pathway.  N Engl J Med. 1999;  340 197-206
• 14 Riddick C A. et al . Dexamethasone increases expression of 5-lipoxygenase and its activating protein in human monocytes and THP-1 cells.  Eur J Biochem. 1997;  246 112-118
• 15 National Asthma Education and Prevention Program, Executive Summary of the Expert Panel Report: Guidelines for the Diagnosis and Management of Asthma - Update on Selected Topics. Bethesda, Md.: National Institutes of Health; National Heart, Lung and Blood Institute Publication No. 02 - 5075 2002
• 16 Salvi S S. et al . The anti-inflammatory effects of leukotriene-modifying drugs and their use in asthma.  Chest. 2001;  119 1533-1546
• 17 Jarvis B. et al . Montelukast: a review of its therapeutic potential in persistent asthma.  Drugs. 2000;  59 891-928
• 18 Cowburn A S. et al . Overexpression of leukotriene C4 synthase in bronchial biopsies from patients with aspirin-intolerant asthma.  J Clin Invest. 1998;  101 834-846
• 19 Dahlén S E. et al . Improvement of aspirin-intolerant asthma by montelukast, a leukotriene antagonist: a randomized, double-blind, placebo-controlled trial.  Am J Respir Crit Care Med. 2002;  165 9-14
• 20 Fowler S J. et al . 5-Lipoxygenase polymorphism and in-vivo response to leukotriene receptor antagonists.  Eur J Clin Pharmacol. 2002;  58 187-190
• 21 Meltzer E O. et al . Concomitant montelukast and loratadine as treatment for seasonal allergic rhinitis: a randomized, placebo-controlled clinical trial.  J Allergy Clin Immunol. 2000;  105 917-922
• 22 Kägi M K. Leukotriene receptor antagonists - a novel therapeutic approach in atopic dermatitis?.  Dermatology. 2001;  203 280-283
• 23 Wettengel. et al . Empfehlungen zur Asthmatherapie bei Kindern und Erwachsenen.  Pneumologie. 1998;  52 52 591-52 601